Re-Study If Re-Study of the Interconnection Facilities Study is required due to a higher queued project dropping out of the queue or a modification of a higher queued project pursuant to Section 4.4, Transmission Provider shall so notify Interconnection Customer in writing. Such Re-Study shall take no longer than sixty (60) Calendar Days from the date of notice. Any cost of Re-Study shall be borne by the Interconnection Customer being re-studied.
Synopsis The agreement authorizes the parties to charter space between South Korea, Japan and the U.S. Pacific Coast. Dated: March 28, 2008. By Order of the Federal Maritime Commission. Xxxxx X. Xxxxxxx, Assistant Secretary. [FR Doc. E8–6796 Filed 4–1–08; 8:45 am] BILLING CODE 6730–01–P FEDERAL MARITIME COMMISSION Ocean Transportation Intermediary License Applicants Notice is hereby given that the following applicants have filed with the Federal Maritime Commission an application for license as a Non-Vessel Operating Common Carrier and Ocean Freight Forwarder—Ocean Transportation Intermediary pursuant to section 19 of the Shipping Act of 1984 as amended (46 U.S.C. Chapter 409 and 46 CFR part 515). Persons knowing of any reason why the following applicants should not receive a license are requested to contact the Office of Transportation Intermediaries, Federal Maritime Commission, Washington, DC 20573. Non-Vessel Operating Common Carrier Ocean Transportation Intermediary Applicants: American International Shipping, 0000 Xxxx Xxxxxxx Xxxxxx, Xxxxxxx, XX 00000. Officers: Xxxxxxx Xxxxxx, President, (Qualifying Individual), Xxxxx Xxxxxxx, Vice President. Freight Masters Overseas, Inc., 8177 XX 00 Xxxxxx, Xxxxx, XX 00000. Officers: Xxxxx X. Xxxxxxx, Managing Director, (Qualifying Individual), Xxxxxxxx Xxxxxxxxx, President. ARC Air Logistics, Inc., 156–15 146th Avenue, Jamaica, NY 11434. Officers: Xxxxxxx Xxxxxxx, President, (Qualifying Individual), Xxxxx Xxxxxxxxx, Secretary. Pacer Container Line, Inc., 0000 Xxxxxxxxx Xxxxx, Xxxxxx, XX 00000. Officers: Xxxxxxx X. Xxxx, Vice President, (Qualifying Individual), Xxxxxxx X. Xxxxxxxxx, President. Airway Express & Hyundai Express, 000 Xxxxxx Xxxx, Burlingame, CA 94010. Xxx Xxxx Xxxx, Sole Proprietor. Transeagle Cargo Logistics Corp., 0000 Xxxx 00 Xxxxxx, Xxxxxxx, XX 00000. Officers: Xxxxxx Xxxxx, Vice President, (Qualifying Individual), Xxxxx Xxxxxxxxx, President. Non-Vessel Operating Common Carrier and Ocean Freight Forwarder Transportation Intermediary Applicant: ACS Logistics USA Inc., 0 Xxxxxxxx Xxx, Xxxxxxxxx, XX 00000.
Drug Plan 42.01 The parties agree to the continuation of the Drug Care plan as follows:
Multiple Measures of Student Learning Measures must include a combination of classroom, school and district assessments, student growth percentiles on state assessments, if state assessments are available, and student MEPA gain scores. This definition may be revised as required by regulations or agreement of the parties upon issuance of ESE guidance expected by July 2012.
Case Study Upon Surgi-Vision’s prior written consent in each Instance, Cedara may devise a case-study of any Custom Engineering Services Projects, and may use such case-study for marketing of its engineering services to third parties.
System Impact Study An assessment by the Transmission Provider of (i) the adequacy of the Transmission System to accommodate a Completed Application, an Interconnection Request or an Upgrade Request, (ii) whether any additional costs may be incurred in order to provide such transmission service or to accommodate an Interconnection Request, and (iii) with respect to an Interconnection Request, an estimated date that an Interconnection Customer’s Customer Facility can be interconnected with the Transmission System and an estimate of the Interconnection Customer’s cost responsibility for the interconnection; and (iv) with respect to an Upgrade Request, the estimated cost of the requested system upgrades or expansion, or of the cost of the system upgrades or expansion, necessary to provide the requested incremental rights.
Implementation of Strategic Plan Goals This Agreement supports the County’s Strategic Plan, Goal 1, Operational Effectiveness/Fiscal Sustainability. This Agreement will provide revenue reimbursement to the Department for services rendered.
Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.
DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK Firms and/or individuals that assisted in the development or drafting of the specifications, requirements, statements of work, or solicitation documents contained herein are excluded from competing for this solicitation. This shall not be applicable to firms and/or individuals providing responses to a publicly posted Request for Information (RFI) associated with a solicitation.
Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.
